Ipamorelin vs Sermorelin
Side-by-Side Comparison
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating... | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / Not approved for human use | Previously FDA-approved (Geref, discontinued); now used off-label via compounding |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 100–300 mcg/day SC |
| Frequency | 2–3 times daily (typically before meals and before bed) | Once daily (typically before bed) |
| Molecular Weight | ~711.9 g/mol | ~3357.9 g/mol |
| Half-Life | ~2 hours | ~10–20 minutes |
Overview
Ipamorelin and Sermorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging, Body Composition, Sleep.
Ipamorelin is also researched for: no additional unique applications.
Sermorelin is also researched for: no additional unique applications.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Related Products
Related Research News
Synergistic Growth Hormone Effects of Sermorelin and Ipamorelin Blend
Research peptides Sermorelin and Ipamorelin may work together to boost growth hormone release from pituitary cells through distinct pathways. Sermorelin mimics the active part of natural GHRH, while Ipamorelin targets GHS-R1a receptors selectively. Laboratory studies indicate this combination could produce higher hGH peaks than either alone, with potential anabolic benefits via IGF-1.
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.